Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations


April 25, 2017
Proc Natl Acad Sci

CTD2 researchers at Dana Farber identify that 2-oxoglutarate dehydrogenase, a tricarboxylic acid cycle enzyme, is crucial to maintain PIK3CA mutant tumor survival or proliferation.

All Programs
April 03, 2017

Scientists demonstrate that  Phosphoinositide 3-kinase enhancer (PIKE)-A directly interacts with CDK4. Furthermore, in vitro and in vivo studies in Glioblastoma (GBM) have shown that PIKE-A/CDK4 complex promotes cell proliferation and tumorigenesis. 

March 22, 2017
Cancer Discovery

Researchers developed a platform that integrates whole exome sequencing with high throughput drug screening in patient-derived tumor organoids. This platform has the potential to identify effective therapeutic strategies for patients where standard treatment options have been exhausted.

March 16, 2017

CTD2 scientists  at Emory University have identified Aurora Kinase A as a novel H-Ras binding partner in enhancing MAPK signaling. This novel protein-protein interaction is a potential therapeutic target in cancer.

March 15, 2017
Marine Drugs

CTD2 researchers at University of Texas Southwestern identify marine bacteria-derived natural product N⁶,N⁶-dimethyladenosine as a potent inhibitor of Akt signaling  in non-small cell lung cancer cell lines. 

All Programs
March 06, 2017
Journal of Experimental Medicine

CTD2 scientists at CSHL characterize intratumoral heterogeneity of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.   

February 23, 2017

Scientists at Dana Farber have performed CRISPR-Cas9 drug resistance screens and identified that loss of KEAP1 expression negates inhibitors targeting RTK/MAPK pathways in Lung cancer. This finding may assist with treatment decisions in managing lung cancer. 

February 23, 2017
Cell Reports

CTD2 researchers at Dana Farber have identified the transcription factor ATXN1-CIC-ETS as a mediator of resistance to MAPK inhibitors in KRAS mutant pancreatic cancer cell lines using genome-scale CRISPR-Cas9 loss-Of-function screens. 

February 22, 2017
Cancer Research

CTD2 scientists at Dana Farber have identified the serine/threonine kinase family member NEK6 as a central mediator in restoring sensitivity to hormone ablation in prostate cancer xenograft models.

February 16, 2017
Nature Communications

The OncoPPi network is a resource of experimentally determined physical protein-protein interactions that builds on cancer genomics for discovery and exploitation of cancer vulnerabilities.